07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Pyridorin pyridoxamine: Phase III started

NephroGenex began the double-blind, placebo-controlled, international Phase III PYR-311 trial to evaluate 300 mg oral Pyridorin twice daily until ESRD or death occurs in about 600 patients with nephropathy due to Type II diabetes. PYR-311...
02:21 , Feb 11, 2014 |  BC Extra  |  Financial News

NephroGenex raises $37.2 million in IPO

Kidney disease company NephroGenex Inc. (NASDAQ:NRX) raised $37.2 million in an IPO through the sale of shares at the low end of its proposed range. NephroGenex sold 3.1 million shares at $12, valuing the company...
02:14 , Jan 22, 2014 |  BC Extra  |  Financial News

Ultragenyx, NephroGenex set IPO terms

Orphan drug company Ultragenyx Pharmaceutical Inc. (Novato, Calif.) and kidney disease company NephroGenex Inc. (Research Triangle Park, N.C.) set IPO terms late Friday. Both companies are seeking to list on NASDAQ. Ultragenyx plans to sell...
00:12 , Dec 24, 2013 |  BC Extra  |  Financial News

Genocea, Auspex, NephroGenex file for IPO

Infectious disease company Genocea Biosciences Inc. (Cambridge, Mass.), rare neurology disease play Auspex Pharmaceuticals Inc. (La Jolla, Calif.) and kidney disease company NephroGenex Inc. (Research Triangle Park, N.C.) all filed to raise money in IPOs....
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Pyridorin pyridoxamine: Phase IIb data

The double-blind, U.S. Phase IIb PYR-210 trial in 307 evaluable patients showed that twice-daily 150 and 300 mg Pyridorin each missed the primary endpoint of significantly reducing the progressive increase in serum creatinine levels from...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Clinical News

Pyridorin: Completed Phase IIb enrollment

NephroGenex completed enrollment of 317 patients in a double-blind, international Phase IIb trial (PYR-210) comparing 150 and 300 mg oral Pyridorin pyridoxamine given twice daily vs. placebo for 1 year. BioStratum granted NephroGenex U.S. and...
07:00 , May 15, 2006 |  BC Week In Review  |  Company News

BioStratum, NephroGenex, Vanderbilt University deal

BioStratum granted NephroGenex U.S. and European rights to diabetic neuropathy compound Pyridorin pyridoxamine for an undisclosed amount of cash and stock. The deal also includes BioStratum's second-generation advanced glycation end-product (AGE) inhibitors, including preclinical compound...
07:00 , Apr 5, 2004 |  BC Week In Review  |  Company News

BioStratum board of directors update

BioStratum Inc. , Research Triangle Park, N.C.   Business: Endocrine   Hired: Kirk Ways as VP and chief development officer, formerly senior global medical director at Aventis S.A. 's Aventis Pharmaceuticals unit  ...
08:00 , Mar 15, 2004 |  BioCentury  |  Strategy

BioStratum

BioStratum Partner Status Compound/Target Disease category Total value (M) Upfront/ Equity (M) Milestones (M) R&D funding Sales Other Novo Nordisk Preclin Anti-laminin 5 antibodies Cancer NA NA $80.0 Undisclosed Royalties Milestone is $80M per antibody...
08:00 , Mar 15, 2004 |  BioCentury  |  Strategy

Early bird deal

Amid the clamor about pharmaceutical companies scouring under rocks to find late-stage products, it's also been increasingly clear that they haven't abandoned early stage deals as the Phase III cupboard gets bare. Of the 52...